Predictors of antibody persistence to the 7-valent pneumococcal conjugate vaccine in healthy Fijian infants at 12 months of age

Little is known about the predictors of antibody persistence to pneumococcal conjugate vaccines (PCV) in the context of reduced dose schedules. In Fiji, an RCT investigated 0, 1, 2 and 3 dose schedules of 7-valent PCV administered at 6, 10 and 14 weeks of age in 364 healthy infants. This study was a...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine Vol. 38; no. 33; pp. 5095 - 5099
Main Authors: Lindholm, Daniel E., Licciardi, Paul V., Ratu, Felisita T., Kim Mulholland, E., Nguyen, Cattram D., Russell, Fiona M.
Format: Journal Article
Language:English
Published: Netherlands Elsevier Ltd 14.07.2020
Elsevier Limited
Subjects:
Age
Allergy and Immunology
Antibiotics
Antibodies
Antibodies, Bacterial
Antigens
Breastfeeding & lactation
Conjugates
Cultural differences
Ethnicity
Families & family life
Family income
Fiji
Health risk assessment
Households
Humans
IgG antibody
Immunoglobulin G
Infant
Infants
nationalities and ethnic groups
odds ratio
Opsonophagocytosis
Pneumococcal conjugate vaccine
Pneumococcal Infections - prevention & control
Pneumococcal Vaccines
Poor antibody persistence
Reduced-dose schedule
risk
Schedules
Streptococcus infections
Streptococcus pneumoniae
Tetanus
Vaccines
Vaccines, Conjugate
Fiji
Pneumococcal conjugate vaccine
PCV
RCT
Fiji
aOR
CI
Poor antibody persistence
IgG
Infant
Reduced-dose schedule
HPV
PCV7
Ethnicity
URTI
OI
immunoglobulin G
7-valent pneumococcal conjugate vaccine
opsonophagocytic index
randomised control trial
adjusted odds ratio
confidence interval
human papillomavirus vaccine
upper respiratory tract infection
ISSN:0264-410X, 1873-2518, 1873-2518
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Little is known about the predictors of antibody persistence to pneumococcal conjugate vaccines (PCV) in the context of reduced dose schedules. In Fiji, an RCT investigated 0, 1, 2 and 3 dose schedules of 7-valent PCV administered at 6, 10 and 14 weeks of age in 364 healthy infants. This study was a post-hoc analysis of the predictors of poor antibody persistence at 12 months, prior to a booster, using univariable and multivariable analyses. The strongest predictors of poor antibody persistence as measured by serotype-specific immunoglobulin G (IgG) and opsonophagocytosis (OI) assays were being of Indigenous Fijian ethnicity (IgG: adjusted odds ratio (aOR) 3.43, p < 0.001; OI: aOR 1.96, p = 0.013) and receipt of fewer than 3 doses of PCV. These findings may help to identify which children may be at an increased risk of pneumococcal disease in the context of reduced dose primary series PCV schedules.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0264-410X
1873-2518
1873-2518
DOI:10.1016/j.vaccine.2020.06.025